Search research articles
Contact Us
Filters
Showing results (171-180 of 266) with videos related to
Page
of 27
Sort By:
European Urology
|
March 7, 2017
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
Bernard Escudier, Padmanee Sharma, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Marek Ziobro, et al.
The Lancet. Oncology
|
September 23, 2014
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial
Cora N Sternberg, Daniel Castellano, Gedske Daugaard, et al.
International Journal of Medical Sciences
|
April 4, 2017
Expression of Sterol Regulatory Element-Binding Proteins in epicardial adipose tissue in patients with coronary artery disease and diabetes mellitus: preliminary study
Luis M Pérez-Belmonte, Inmaculada Moreno-Santos, Fernando Cabrera-Bueno, et al.
ESMO Open
|
November 28, 2020
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
Laurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
Future Oncology (London, England)
|
September 17, 2020
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer
Robert A Huddart, Arlene O Siefker-Radtke, Arjun V Balar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 22, 2021
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial
Karim Fizazi, Pablo González Mella, Daniel Castellano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2016
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
Thomas Powles, Mark R Lackner, Stéphane Oudard, et al.
European Journal of Endocrinology
|
November 30, 2023
Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival
Anna La Salvia, Alberto Lens-Pardo, Angel López-López, et al.
BMC Cancer
|
November 3, 2023
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study
Do-Youn Oh, Maria Alsina Maqueda, David I Quinn, et al.
Page
of 27
Search research articles
Search
Showing results (171-180 of 266) with videos related to
Sort By:
Page
of 27
European Urology
|
March 7, 2017
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
Bernard Escudier, Padmanee Sharma, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Marek Ziobro, et al.
The Lancet. Oncology
|
September 23, 2014
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial
Cora N Sternberg, Daniel Castellano, Gedske Daugaard, et al.
International Journal of Medical Sciences
|
April 4, 2017
Expression of Sterol Regulatory Element-Binding Proteins in epicardial adipose tissue in patients with coronary artery disease and diabetes mellitus: preliminary study
Luis M Pérez-Belmonte, Inmaculada Moreno-Santos, Fernando Cabrera-Bueno, et al.
ESMO Open
|
November 28, 2020
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
Laurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
Future Oncology (London, England)
|
September 17, 2020
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer
Robert A Huddart, Arlene O Siefker-Radtke, Arjun V Balar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 22, 2021
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial
Karim Fizazi, Pablo González Mella, Daniel Castellano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2016
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
Thomas Powles, Mark R Lackner, Stéphane Oudard, et al.
European Journal of Endocrinology
|
November 30, 2023
Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival
Anna La Salvia, Alberto Lens-Pardo, Angel López-López, et al.
BMC Cancer
|
November 3, 2023
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study
Do-Youn Oh, Maria Alsina Maqueda, David I Quinn, et al.
Page
of 27